ASTRAZENECA ENTERS CO-PROMOTION AGREEMENT WITH JANSSEN IN JAPAN FOR INNOVATIVE PROSTATE CANCER TREATMENT

ASTRAZENECA ENTERS CO-PROMOTION AGREEMENT WITH JANSSEN IN JAPAN FOR INNOVATIVE PROSTATE CANCER TREATMENT
 
11 October 201
AstraZeneca today announced that it has entered into an agreement with Janssen Pharmaceuticals K. K. in Japan to co-promote abiraterone acetate, an innovative oral therapy for the treatment of patients with prostate cancer.
 
Currently the main treatment option available to patients in Japan is medical castration, however prostate cancer can still progress in many patients because androgens are produced in other tissues. Abiraterone acetate, a CYP17-inhibitor, inhibits the key enzyme which modulates the production of androgens, hormones which stimulate prostate cancer cells to grow, from all sources in the body. This helps lower the level of androgens available to the prostate cancer cells, which is the goal of treatment in prostate cancer.
 
Janssen Pharmaceuticals K.K. submitted a marketing approval application for abiraterone acetate to the Japanese Ministry of Health, Labour and Welfare in July 2013 for the treatment of prostate cancer. The product was approved in the US by the Food and Drug Administration in April 2011, and in the EU by the European Commission in September 2011 for the treatment of patients with metastatic castration-resistant prostate cancer.
 
Marc Dunoyer, Executive Vice President, Global Products and Portfolio Strategy at AstraZeneca said: "Japan is one of the fastest growing pharmaceutical markets, where AstraZeneca has a proven track record of successfully developing and marketing innovative medicines. Abiraterone acetate is a great addition to our existing portfolio of leading cancer treatments, with real potential to address an important and growing patient need. This deal is a strong strategic fit for AstraZeneca, reinforcing both our focus on oncology as a core therapy area and Japan as one of our key growth drivers."
 
Financial terms of the agreement were not disclosed.
 
– ENDS –
 
NOTES TO EDITORS
 
About abiraterone acetate
 
Abiraterone acetate is indicated in the US and the EU for the treatment of patients with metastatic castration-resistant prostate cancer in combination with prednisone (steroid) before and after treatment with docetaxel (chemotherapy). Abiraterone acetate has been approved in 83 countries.
 
About AstraZeneca
 
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
 
CONTACTS
 
Media Enquiries
 
Ayesha Bharmal                         +44 20 7604 8034 (UK/Global)
 
Esra Erkal-Paler                         +44 20 7604 8030 (UK/Global)
 
Laura Woodin                             +1 302 885 1087 (US)
 
Michele Meixell                          +1 302 885 2677 (US)
 
Jacob Lund                                 +46 8 553 260 20 (Sweden)
 
Investor Enquiries
 
Ed Seage                                    +1 302 886 4065      mob:  +1 302 373 1361
 
Karl Hård                                    +44 20 7604 8123  mob: +44 7789 654364
 
Colleen Proctor                           + 1 302 886 1842     mob:  +1 302 357 4882
 
Anthony Brown                            +44 20 7604 8067    mob: +44 7585 404943
 
Jens Lindberg                             +44 20 7604 8414    mob: +44 7557 319729

Suggested Articles

After a slow start, Teva's Ajovy launch is improving following the FDA approval for an autoinjector.

After Trump's "Buy American" executive order for essential medicines, the pharma industry is pushing back.

The U.S. is slamming the brakes on its $765 million loan to Kodak amid insider trading allegations and questions about its fitness for the job.